J
J F San Miguel
Researcher at University of Navarra
Publications - 337
Citations - 16328
J F San Miguel is an academic researcher from University of Navarra. The author has contributed to research in topics: Multiple myeloma & Transplantation. The author has an hindex of 68, co-authored 336 publications receiving 15213 citations. Previous affiliations of J F San Miguel include Leiden University & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Antonio Palumbo,S V Rajkumar,Meletios A. Dimopoulos,Paul G. Richardson,J F San Miguel,Bart Barlogie,J L Harousseau,Jeffrey A. Zonder,Michele Cavo,Maurizio Zangari,M. Attal,Andrew Belch,S. Knop,Douglas E. Joshua,Orhan Sezer,Heinz Ludwig,David H. Vesole,J. Bladé,Robert A. Kyle,Jan Westin,Donna M. Weber,Sara Bringhen,Ruben Niesvizky,Anders Waage,M. von Lilienfeld-Toal,Sagar Lonial,Gareth J. Morgan,Robert Z. Orlowski,Kazuyuki Shimizu,KC Anderson,Mario Boccadoro,Brian G.M. Durie,Pieter Sonneveld,Mohamad A. Hussein +33 more
TL;DR: This manuscript summarizes the available evidence and recommends a prophylaxis strategy according to a risk-assessment model for venous thromboembolism (VTE), and recommends low-molecular-weight heparin (LMWH), warfarin or aspirin.
Journal ArticleDOI
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
Robert A. Kyle,Brian G.M. Durie,S V Rajkumar,Ola Landgren,J. Bladé,Giampaolo Merlini,N Kröger,H. Einsele,David H. Vesole,Meletios A. Dimopoulos,J F San Miguel,Hervé Avet-Loiseau,Roman Hájek,Wenming Chen,Kenneth C. Anderson,Heinz Ludwig,Pieter Sonneveld,Santiago Pavlovsky,Antonio Palumbo,Paul G. Richardson,Bart Barlogie,P R Greipp,Robert Vescio,Ingemar Turesson,Jan Westin,Mario Boccadoro +25 more
TL;DR: Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of residents of Olmsted County, Minnesota, 50 years of age or older and is characterized by having an M protein <15 g/l, IgG type and a normal free light chain (FLC) ratio.
Journal ArticleDOI
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Philippe Moreau,J F San Miguel,Pieter Sonneveld,Maria-Victoria Mateos,Elena Zamagni,Hervé Avet-Loiseau,Roman Hájek,Meletios A. Dimopoulos,Heinz Ludwig,H. Einsele,Sonja Zweegman,Thierry Facon,Michele Cavo,Evangelos Terpos,H. Goldschmidt,M. Attal,Christian Buske +16 more
TL;DR: These Clinical Practice Guidelines are endorsed by the Japanese Society of Medical Oncology (JSMO) incidence and epidemiology Multiple myeloma accounts for 1% ofall cancers and ∼10% of all haematological malignancies.
Journal ArticleDOI
Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients.
Guillermo Sanz,Miguel A. Sanz,Teresa Vallespi,María Consuelo del Cañizo,M. Torrabadella,S. García,D. Irriguible,J F San Miguel +7 more
TL;DR: These regression models and the simpler scoring system may be accurately used for decision-making regarding therapy in MDS patients by demonstrating its capability of segregating patients into low-, intermediate-, and high-risk groups, with distinctively different survival curves.
Journal ArticleDOI
Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia
S. de Botton,Hervé Dombret,Miguel A. Sanz,J F San Miguel,Denis Caillot,R. Zittoun,Martine Gardembas,Aspasia Stamatoulas,Eulogio Conde,Agnès Guerci,C. Gardin,K Geiser,D. Cony Makhoul,Oumedaly Reman,J. de la Serna,François Lefrère,Christine Chomienne,Claude Chastang,Laurent Degos,Pierre Fenaux +19 more
TL;DR: In this multicenter trial where CT was rapidly added to ATRA in case of high or increasing WBC counts and DXM generally also used at the earliest clinical sign, the incidence of ATRA Syndrome was 15%, but ATRA syndrome was responsible for death in only 1.2% of the total number of patients treated.